Fibrinogen Binding Inhibitor Peptide

Fibrinogen Binding Inhibitor Peptide (CPC catalog code RGDP-006) is a synthetic cell adhesion / ecm peptide in the cell adhesion category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.

Published and internal research programs use Fibrinogen Binding Inhibitor Peptide as a reference standard in cell adhesion workflows — for example, integrin engagement and blocking studies and migration and wound-closure assays. Human clinical evidence is not established.

No. Fibrinogen Binding Inhibitor Peptide is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.

In a cell adhesion workflow, Fibrinogen Binding Inhibitor Peptide is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. Typically used in coated-plate attachment assays, transwell migration, and SPR / BLI integrin-binding measurements.

Store lyophilized at −20 °C. Peptides are hygroscopic — desiccate before opening. Follow your institution's standard operating procedures for handling synthetic peptides.

This kindr reference page mirrors CPC Scientific's catalog metadata for RGDP-006. The upstream reference sheet — including sequence, purity, MW, and application notes where published — is linked from the buy panel. All orders placed on kindr Peptides ship internationally under research-use terms only.

Research-grade peptides in the CPC catalog are synthesized by solid-phase peptide synthesis (SPPS), purified by preparative RP-HPLC, and characterized by analytical HPLC and mass spectrometry. Typical purity is ≥95%; certificate of analysis is available on request.